PKM and familial pancreatic carcinoma: Because dimeric PKM2 acts mainly as a transcriptional regulator in cancer cells, PKM2 activators which promote the formation of tetrameric PKM2 may be effective in suppressing non-metabolic function of PKM2 and reducing resistance to gemcitabine in pancreatic cancer cells.